Silver Book Fact

Use of pneumonia vaccine in children reduced rates in adults age 65+

Within a year of introduction of PCV7 (7-valent pneumococcal conjugate vaccine) for use in the U.S. in infants, children under 2 years, and high risk children ages 2 to 4; invasive pneumococcal disease rates in unvaccinated individuals age 65 and older fell by 18%.

Whitney C, Farley M, Hadler J, Harrison L, et al. Decline in Invasive Pneumococcal Disease After the Introduction of Protein-Polysaccharide Conjugate Vaccine. N Engl J Med. 2003; 348(18): 1737-46. http://www.nejm.org/doi/full/10.1056/NEJMoa022823

Reference

Title
Decline in Invasive Pneumococcal Disease After the Introduction of Protein-Polysaccharide Conjugate Vaccine
Publication
N Engl J Med
Publication Date
2003
Authors
Whitney C, Farley M, Hadler J, Harrison L, et al
Volume & Issue
Volume 348, Issue 18
Pages
1737-46
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Eradication of infectious diseases from vaccination
    Spanning more than 200 years of research and development, 10 infectious diseases have been at least 90 percent eradicated in the United States thanks to vaccines.  
  • Staff flu vaccination reduces incidence of staff and patients
    Vaccination of staff in a tertiary care facility over a period of 12 influenza seasons increased vaccination coverage from 4% to 67%, reduced laboratory-confirmed cases of influenza amongst staff from…  
  • Cost effectiveness of MMR vaccine
    For every dollar spent on the MMR (measles, mumps, and rubella) vaccine, $21 is saved.  
  • Only a 20% reduction in drug-resistant infections would save $3.2 – $5.2 billion each year
    A 20% reduction in drug-resistant infections would save between 5.7 and 11.3 million additional hospital days and between $3.2 and $5.2 billion in healthcare costs, each year.  
  • Potential cost effectiveness of shingles vaccines
    The projected cost-effectiveness of a shingles vaccine for adults age 60 and older was estimated at $15,390 – $22,474 from the payer perspective, and $14,450 to $21,524 from the societal…